Duleek Ranatunga

Duleek Ranatunga has extensive experience in the fields of computational biology, cancer research, and entrepreneurship. Duleek is the Founder and CEO of Pear Bio, a VC-backed company that utilizes organ-on-a-chip and computer vision technology to study the human tumor microenvironment and its impact on cancer progression. Duleek is also a Writer for "Why there's not a single cure for cancer" and served as an Entrepreneur in Residence for Merck Group. Prior to this, they worked as a Growth Manager for Clearco, a Co-Founder at Ourotech, and an Entrepreneur in Residence at Singularity University. Duleek's background also includes managerial experience at a stealth startup and a research fellowship at the University of Waterloo, where they focused on hydrogels for tissue engineering. Duleek co-founded Hydrosole, participated in nanomaterial-based water treatment research, and played a key role in the development of foundational technologies for science startups.

Duleek Ranatunga has a diverse education history. In 2013, they attended the University of Waterloo, where they pursued a degree in Nanotechnology Engineering. After their time at Waterloo, there is no information available regarding their educational pursuits until 2017 when they attended Singularity University. At Singularity University, Duleek focused on Entrepreneurial and Small Business Operations. Most recently, Duleek attended Stanford University School of Medicine to study Medical Statistics, completing their education in 2019.